Fideuram Intesa Sanpaolo Private Banking S.P.A. Has $1.74 Million Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA

Fideuram Intesa Sanpaolo Private Banking S.P.A. increased its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 3,237.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 116,812 shares of the company’s stock after purchasing an additional 113,312 shares during the quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. owned approximately 0.13% of Olema Pharmaceuticals worth $1,742,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. AQR Capital Management LLC acquired a new stake in shares of Olema Pharmaceuticals in the first quarter valued at approximately $172,000. Goldman Sachs Group Inc. raised its stake in Olema Pharmaceuticals by 93.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock valued at $2,787,000 after acquiring an additional 358,412 shares during the period. Jane Street Group LLC lifted its holdings in Olema Pharmaceuticals by 216.8% during the 1st quarter. Jane Street Group LLC now owns 138,552 shares of the company’s stock valued at $521,000 after purchasing an additional 94,815 shares during the last quarter. Geode Capital Management LLC boosted its position in Olema Pharmaceuticals by 22.4% during the second quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after purchasing an additional 242,997 shares during the period. Finally, Creative Planning bought a new position in Olema Pharmaceuticals during the second quarter worth $83,000. Institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on OLMA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. increased their price target on shares of Olema Pharmaceuticals from $55.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, March 18th. The Goldman Sachs Group reduced their price objective on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Guggenheim dropped their price target on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Finally, Jefferies Financial Group started coverage on Olema Pharmaceuticals in a report on Thursday, March 19th. They issued a “buy” rating and a $40.00 price objective on the stock. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Olema Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $44.10.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA opened at $12.64 on Friday. The stock’s fifty day moving average is $12.43 and its 200 day moving average is $18.77. Olema Pharmaceuticals, Inc. has a 52 week low of $4.37 and a 52 week high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. The stock has a market capitalization of $1.10 billion, a P/E ratio of -6.26 and a beta of 2.00.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). Sell-side analysts forecast that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.